Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells
- 1 February 2000
- journal article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 78 (2) , 134-142
- https://doi.org/10.1139/y99-125
Abstract
Aiming to develop a functional assay for the human NPY Y5 receptor based on adenylyl cyclase activity, HEC-1B cells, in which cAMP synthesis can be efficiently stimulated with forskolin, were selected for the transfection with the pcDNA3-Y5-FLAG and the pcDEF3-Y5 vectors. After optimization of the transfection procedure, the binding of [3H]propionyl-NPY to transiently and stably expressed Y5 receptors was determined. The affinities of NPY, NPY derivatives, and rPP (pNPY >= p(Leu31Pro34)NPY = p(2-36)NPY >= p(D-Trp32)NPY > p(13-36)NPY > rPP) were in accordance with the NPY Y5 receptor subtype. For [3H]propionyl-pNPY approximately 1.7 × 105 and 1 × 106 binding sites per transiently and stably transfected cell, respectively, were determined. The KD values were 2.4 ± 0.4 and 1.7 ± 0.2 nM, respectively. Due to the high expression of the receptor protein, both stably and transiently transfected cells can be conveniently used in routine radioligand binding studies. By contrast, functional assays were only feasible with HEC-1B cells stably expressing the Y5 receptor. In these cells, 10 nM pNPY inhibited the forskolin-stimulated cAMP synthesis by 75%. This effect was partially antagonized by the Y5 antagonist N-{trans-[4-(2-naphthylmethylamino)- methyl]cyclohexylmethyl}naphthalene-2-sulfonamide. Although the genetic variability of cancer cells is in principle incompatible with a stable phenotype, both ligand binding characteristics and functionality of the Y5 receptor remained unchanged for more than 30 passages.Key words: human NPY Y5 receptor, HEC-1B cells, stable expression, radioligand binding, cAMP assay.Keywords
This publication has 13 references indexed in Scilit:
- Emerging functions for neuropeptide Y5 receptorsTrends in Pharmacological Sciences, 1999
- NPY Y1 antagonists: structure–activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structuresRegulatory Peptides, 1998
- Molecular biology and pharmacology of multiple NPY Y5 receptor species homologsRegulatory Peptides, 1998
- GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonistsEuropean Journal of Pharmacology, 1998
- Overlapping Gene Structure of the Human Neuropeptide Y Receptor Subtypes Y1 and Y5 Suggests Coordinate Transcriptional RegulationGenomics, 1997
- Neuropeptide Y Family of Hormones: Receptor Subtypes and AntagonistsPeptides, 1997
- A receptor subtype involved in neuropeptide-Y-induced food intakeNature, 1996
- An Enzymatic Fluorometric Assay for Adenosine 3′:5′-MonophosphateAnalytical Biochemistry, 1994
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Establishment of a cell line of human endometrial adenocarcinoma in vitroAmerican Journal of Obstetrics and Gynecology, 1972